Physician profile
Niku Singh
NPI 1558374595
$2,463,730.67
in general payments reported to CMS, 2019-2025
30 companies · $608K in 2025
The $608K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152K · 2020: $122K · 2021: $223K · 2022: $427K · 2023: $463K · 2024: $469K · 2025: $608K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $906K · Travel and Lodging: $311K · Consulting Fee: $175K · Honoraria: $109K · Food and Beverage: $39K · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $906,026.55 |
| Travel and Lodging | $310,673.85 |
| Consulting Fee | $174,712.50 |
| Honoraria | $109,275.00 |
| Food and Beverage | $39,457.57 |
| Education | $102.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771,011.27 | 2021-2025 | Vraylar, Qulipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $593,560.15 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $317,587.07 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $296,359.97 | 2019-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $147,740.67 | 2019-2021 | |
| Alkermes, INC. | $143,352.49 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $120,272.64 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $42,980.70 | 2019-2025 | Trintellix |
| Eisai INC. | $17,718.62 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $2,859.87 | 2020-2024 | Jornay Pm |
| Lundbeck LLC | $1,625.27 | 2019-2025 | Rexulti, Brintellix |
| Vanda Pharmaceuticals INC. | $1,568.09 | 2019-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $1,414.35 | 2020-2024 | Aplenzin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,320.96 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $1,175.18 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $678.48 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $585.37 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $435.97 | 2021-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $376.47 | 2019-2023 | Spravato |
| Corium, LLC | $349.22 | 2022-2023 | Adlarity, Azstarys |
| Avanir Pharmaceuticals, INC. | $218.80 | 2020-2021 | |
| Shire North American Group INC | $157.29 | 2019 | |
| Merck Sharp & Dohme LLC | $155.02 | 2020-2022 | |
| Sage Therapeutics, LLC | $86.55 | 2020 | |
| Adlon Therapeutics L.P. | $39.91 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.82 | 2019 | |
| Aytu Biopharma, INC. | $22.21 | 2021 | |
| Idorsia Pharmaceuticals US INC | $20.00 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.87 | 2021 | |
| Neurocrine Biosciences, INC. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niku Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.